Company Performance Metrics
- Matthew R. Gevaert: Co-founder & CEO
- Lillia Holmes: Chief Operations Officer
KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is a
single-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.
